12XU6D9Flm | 1802909-49-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 12XU6D9Flm
• 英文别名: 1-[[4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid
• CAS: 1802909-49-4
• 化学式: C₂₃H₃₄N₂O₃
• 分子量: 386.5
• InChiKey: WBPWDDPSYSUQJA-VQTJNVASSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] SALTS OF AN LSD1 INHIBITOR<br/>[FR] SELS D'UN INHIBITEUR DE LSD1
  申请人：INCYTE CORP

  公开号：WO2017027678A1

  公开（公告）日：2017-02-16

  The present disclosure relates to tosylate salts 1-[4-(methoxymethyl)-4-([(1R,2S)-2- phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the LSD1-associated or mediated diseases such as cancer.

  本公开涉及对甲氧甲基-4-([(1R,2S)-2-苯基环丙基]氨基}甲基)哌啶-1-基甲基}环丁烷羧酸对甲磺酸盐的制备方法及其制备中的中间体，这些中间体在治疗LSD1相关或介导的疾病如癌症方面具有用途。
• FORMULATIONS OF AN LSD1 INHIBITOR
  申请人：Incyte Corporation

  公开号：US20170304282A1

  公开（公告）日：2017-10-26

  The present application relates to pharmaceutical formulations and dosage forms of a lysine specific demethylase-1 (LSD1) inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of LSD1 mediated diseases such as cancer.

  本申请涉及一种赖氨酸特异性去甲基化酶-1（LSD1）抑制剂的药物配方和剂型，或其药用可接受的盐、溶剂化合物或水合物，包括其制备方法，这些方法在治疗LSD1介导的疾病如癌症中是有用的。
• [EN] FORMULATIONS OF AN LSD1 INHIBITOR<br/>[FR] FORMULATIONS D'UN INHIBITEUR DE LSD1
  申请人：INCYTE CORP

  公开号：WO2017184934A1

  公开（公告）日：2017-10-26

  The present application relates to pharmaceutical formulations and dosage forms of a lysine specific demethylase-1 (LSD1) inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of LSD1 mediated diseases such as cancer.

  本申请涉及一种赖氨酸特异性去甲基化酶-1（LSD1）抑制剂的制药配方和剂型，或其在药用上可接受的盐、溶剂合物或水合物，包括其制备方法，该制备方法在治疗LSD1介导的疾病如癌症方面具有用处。
• CYCLOPROPYLAMINES AS LSD1 INHIBITORS
  申请人：INCYTE CORPORATION

  公开号：US20150225401A1

  公开（公告）日：2015-08-13

  The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

  本发明涉及环丙胺衍生物，其为LSD1抑制剂，可用于治疗癌症等疾病。
• Formulations of an LSD1 inhibitor
  申请人：Incyte Corporation

  公开号：US10166221B2

  公开（公告）日：2019-01-01

  The present application relates to pharmaceutical formulations and dosage forms of a lysine specific demethylase-1 (LSD1) inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of LSD1 mediated diseases such as cancer.

  本申请涉及赖氨酸特异性去甲基化酶-1（LSD1）抑制剂或其药学上可接受的盐、溶液或水合物的药物制剂和剂型，包括其制备方法，可用于治疗 LSD1 介导的疾病，如癌症。